Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents.
about
Cytochrome P450 ω-Hydroxylases in Inflammation and CancerCoordinating Role of RXRα in Downregulating Hepatic Detoxification during Inflammation Revealed by Fuzzy-Logic ModelingAssessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative ColitisPhysiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme ActivityImpact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patientsThe Promises of Quantitative Proteomics in Precision MedicineRegulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO).4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and Correlation With Inflammatory State.Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window.Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.CYP3A activity: towards dose adaptation to the individual.Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective.Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.Biological Response Modifier in Cancer Immunotherapy.Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma.Use of microdose phenotyping to individualise dosing of patients.Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.A novel drug interaction between busulfan and blinatumomab.Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs.Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.
P2860
Q26800210-9513DE5A-FACB-498D-863B-D8B5388F6045Q28551973-D6AD070A-8FD2-4A8B-A458-24E5F5080D31Q28597396-9F6172AA-B30C-4D3B-A9D8-616C353AC309Q36118294-FF04B456-548A-41FE-958A-19C35A259E79Q36243677-75273BD4-2921-42D0-87D1-3CBD3ED3963BQ37647264-E61938F6-40EE-45CA-B192-D5842F367FEFQ37689738-01BF5CFD-C2C5-4EE3-AA33-BC9AAC20FEC1Q37700667-1A040588-4D10-4BBE-9B35-B36F85A7AF6EQ38390695-E3C2B853-803A-4C5F-992A-F73A03D9DBACQ38634986-DBA31FE8-D729-4AFF-B544-30B574CFB6A7Q38763583-EB4AE3DE-AB2C-4458-9EFE-2ED1093295B0Q38800092-D7C2CE35-9BCA-4A0B-89D2-E8267A59B9C7Q38803026-EF7408F5-42B2-4F31-8162-AFC59B45196AQ38848213-CCE3A477-E05E-4212-934B-2E4A2345CC1FQ38937177-0F8A6A39-3529-4E7F-AEA7-4FC02A628411Q38972539-B8A558FD-9FEB-4A06-93CF-9ECC974D031CQ39582357-15CDB1A9-5A21-4FF6-92D5-83E53A481B86Q40996401-3C08ED2A-9250-4DEB-B49A-85738EE28CA5Q46169240-1A74DC8E-2358-427B-9D22-DA6FF7948664Q47568807-50B0EC59-E836-4F5C-B091-BC11396311C3Q47877881-82B3DCB6-5501-472F-A456-7CD1B42DA110Q50074569-D98E4B16-21A5-4312-926F-AC4C58ADA443Q53513271-5329323B-2C8C-4FB3-A057-C9A8BB3F9652Q55280979-2A8D551E-2F4E-4D34-97D0-DA6A58EDA9D3Q55439721-1E0B6BF8-0740-4056-BB52-ACD74CB821A1
P2860
Cancer, inflammation, and therapy: effects on cytochrome p450-mediated drug metabolism and implications for novel immunotherapeutic agents.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cancer, inflammation, and ther ...... ovel immunotherapeutic agents.
@en
type
label
Cancer, inflammation, and ther ...... ovel immunotherapeutic agents.
@en
prefLabel
Cancer, inflammation, and ther ...... ovel immunotherapeutic agents.
@en
P2860
P356
P1476
Cancer, inflammation, and ther ...... novel immunotherapeutic agents
@en
P2093
R Donald Harvey
P2860
P304
P356
10.1038/CLPT.2014.143
P407
P577
2014-07-02T00:00:00Z